FDA Press Releases·Oct 20, 2026, 9:03 AM ET

FDA Issues Final Guidance on Prescription Drug Apps and Software

The U.S. Food and Drug Administration released final guidance on October 20, 2026, establishing a framework for developing, distributing, & labeling apps used with prescription medicines.
The guidance clarifies when app content requires FDA submission, when it must appear on a drug's official label, & what companies must submit to the agency.
Two categories of companion software were identified: apps connected to medical devices generally require description on the official prescribing label due to their central role in medicine use.
Standalone apps such as symptom trackers or dose reminders should appear on the prescribing label only if essential for safe & effective use or if they demonstrate meaningful clinical benefit.
Most content displayed by companion apps will be treated as promotional material consistent with FDA handling of other drug advertising.
The agency aims to reduce uncertainty for developers while ensuring accurate, evidence-based information is communicated to patients & providers.
This framework aligns approaches across drug & device centers to support the responsible oversight of rapidly evolving digital health technologies.
The final guidance is available via the provided link, with media inquiries directed to the FDA's press office.